Topical tacrolimus is not effective in chronic plaque psoriasis: A pilot study

Archives of Dermatology

Volumn 134, Issue 9, 1998, Pages 1101-1102

  Zonnevdd, Ingrid M ^a   Rubins, Andris ^b   Jablonska, Stephanie ^g   Dobozy, Attila ^c   Ruzicka, Theo ^d   Kind, Peter ^e   Dubertret, Louis ^f   Bos, Jan D ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b RIGA STRADINS UNIVERSITY   (Latvia)

^c UNIVERSITY OF SZEGED   (Hungary)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f SAINT LOUIS HOSPITAL   (France)

^g Klinika Dermatologiczna Medical University of Warsaw   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; CYCLOSPORIN A; TACROLIMUS;

ARTICLE; DRUG EFFICACY; DRUG FORMULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSORIASIS; REMISSION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; CHRONIC DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PILOT PROJECTS; PSORIASIS; TACROLIMUS;

EID: 0031693833     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.134.9.1101     Document Type: Article

References (13)

1. Bos JD, Meinardi MMHM, v Joost Th, et al. Use of cyclosporin in psoriasis. Lancet. 1989;2:1500-1502.
2. Witkamp L, Zonneveld IM, Jung EG, et al. Efficacy and tolerability of multiple-dose SDZ IMM125 in patients with severe psoriasis. Br J Dermatol. 1995;133: 95-103.
3. Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Abu-Elmagd K, Starzl TE. Tacrolimus (FK506): a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol. 1992;128:781-785.
4. European FK506 Multicentre Psoriasis Study Group. Systemic tacrolimus is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol. 1996;132:419-423.
5. Griffiths CE, Powles AV, Baker BS, Fry L, Valdimarsson H. Topical cyclosporin and psoriasis [letter]. Lancet. 1987;1:806.
6. De Prost A, Bodemer C, Teillac D. Randomized double-blind placebo-controlled trial of local cyclosporin in atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1989;144:136-138.
7. De Rie MA, Meinardi MMHM, Bos JD. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis. Acta Derm Venereol Suppl (Stockh). 1991;71:452-454.
8. Rappersberger K, Meingassner JG, Fialla R, et al. Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol. 1996;106:701-710.
9. Aoyama H, Tabata N, Tanaka M, Uesugi Y, Tagami H. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br J Dermatol. 1995;133:494-496.
10. Lauerma AI, Maibach HI, Granlund H, Erkko P, Kartamaa M, Stubb S. Inhibition of contact allergy reactions by topical FK506. Lancet. 1992;340:556.
11. Meingassner JG, Stutz A. Immunosuppressive macrolides of the type FK506: a novel class of topical agents for treatment of skin diseases. J Invest Dermatol. 1992;98:851-855.
12. Ruzicka T, Bieber T, Schopf E, for the European Tacrolimus Multicenter Atopic Dermatitis Study Group. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med. 1997;337:816-821.
13. Remitz A, Reitamo S, Erkko P, et al. A microplaque assay-based, double-blind trial to compare the efficacy of two tacrolimus ointment formulations with two active and two negative controls in patients with chronic plaque-type psoriasis vulgaris [abstract]. Br J Dermatol. 1996;135:833.